Pediatric ophthalmology: Real stories of how Eyer has made a difference in the care of infants and children

Pediatric ophthalmology: Real stories of how Eyer has made a difference in the care of infants and children

Undoubtedly, one of the obstacles in pediatric ophthalmology is being able to carry out examinations on little ones. After all, it can be difficult to keep a child still for examinations.

This difficulty is routine for ophthalmologist, Dr. Patrícia de Freitas Dotto, MD, PhD at the Dr. Jeser Amarante Faria Children’s Hospital, at the São José Municipal Hospital (HMSJ) and in her office, all in Joinville (SC), and at the Lavinsky clinic in Porto Alegre (RS).

“The main challenge is the non-mydriatic fundoscopic evaluation of children between ten months and three years old without sedation or restraint. That’s why it’s essential to create a playful and calm environment that brings peace of mind to the whole family. In this context, photographic documentation, or even fundoscopic imaging, in real time allows parents to be involved in the care, which improves the doctor-patient relationship and, consequently, has a positive impact on the child’s follow-up and/or treatment.”

Dotto says that she uses the Eyer portable fundus camera to speed up examinations on pediatric patients. The equipment, which is very suitable for examining infants and children due to its portability and high image quality, works in conjunction with a smartphone and performs retinal examinations in a few minutes. These photographs are then available on the EyerCloud online platform, making it easier to study and monitor the progression of cases.

“The field of vision is excellent. Under medicated mydriasis, it is also an excellent complementary propaedeutic tool for assessing the mid-periphery of the retina, particularly small hyperpigmented lesions of the choroid (nevus) and retina (melanocytomas), using it as an infrared scan,” she explains.

In her office, with help of the Eyer Slit Lamp Adapter, the ophthalmologist attaches the device to her slit lamp allowing exams to be performed more easily. “Although I really enjoy using it this way, it’s magical to use it in ‘mobile’ form in ICUs, operating rooms, home care and within the office itself, such as evaluations of children on their mother’s lap or in the waiting room,” she points out.

The doctor also uses the Eyer in the emergency room, in adult and child care, for documenting infectious diseases and Retinopathy of Prematurity (ROP) in neonatal ICUs severely debilitated adults in ICUs, as well as inter-consultations for neurology, neurosurgery, nephrology, cardiology, and in medical expertise for the National Civil Aviation Agency (ANAC) and the Santa Catarina Court of Justice (TJSC). “I literally carry Eyer in my bag. It makes my job a lot easier,” she says.

Oftalmologista Patricia Dotto

The ophthalmologist, Dr. Patrícia de Freitas Dotto, MD, PhD treats infants and children at the Dr. Jeser Amarante Faria Children’s Hospital, the São José Municipal Hospital (HMSJ) and at her office, all in Joinville (SC).

Shaken Baby Syndrome

With daily use of the Eyer in various locations, Dotto has witnessed several remarkable cases, such as the care of a child suffering from Shaken Baby Syndrome. The syndrome occurs when the baby is shaken intensely, causing permanent brain damage or even death.

Here’s the doctors report on the case of shaken baby syndrome:

“The child had been followed up for a few months in hospital for convulsions and severe malnutrition. The suspicion of Shaken Baby was raised when neuroimaging alterations (hematoma) were observed during the complementary investigation of status epilepticus.

During the ophthalmological assessment, when I examined her visual acuity (grating), I found that the vision in one eye was outside the normal range for her age, despite the fact that she had no changes in ocular motility.

When I laid her on the gurney for the retinal mapping, she started crying desperately. It was a very difficult examination and I was struck by the fact that the child eventually let go, almost gave up, and then reacted again, without showing any change in her level of consciousness.

It was at one of these moments that I managed to photograph the fundus of the eye and identify retinal lesions, indicating serious damage to the central nervous system. In one particular case, the hemorrhage was very small, probably because it was being reabsorbed, and I could only be sure of the diagnosis because of the examination. It was a miracle for me and for her.

I was devastated that day, but very grateful to HaShem and Phelcom [the company that invented the Eyer]. The case was really investigated from a social point of view, the assaults were confirmed and the appropriate measures were taken.

We saved a life. And in my religion, Judaism, saving a life means saving the whole world.”

Next, see the images of this case taken by Dotto with Eyer:

Img Imagem De Fundo De Olho Feita Com O Eyer De Bebe Vitima De Shaken Baby Syndrome

Img Imagem De Fundo De Olho Feita Com O Eyer De Bebe Vitima De Shaken Baby Syndrome 4

Img Imagem De Fundo De Olho Feita Com O Eyer De Bebe Vitima De Shaken Baby Syndrome 2

Img Imagem De Fundo De Olho Feita Com O Eyer De Bebe Vitima De Shaken Baby Syndrome 3

More cases

Dotto performs retinography on all patients, as she considers it important the normal state of the retina. “We often look for illnesses and forget how important it is to make sure the fundus of the eye is normal, because problems happen throughout life and it’s important to make sure of the moment when the state of eye health is lost,” she says. 

She highlights the case of a 22-year-old woman who was admitted to the ER with compromised visual acuity, severe hypertensive retinopathy and serous detachment of the macula. The team suspected Autoimmune Nephropathy (IgA). “Unbelievably, four or five days after pressure control (in the ICU), she progressed to 20/20 visual acuity and total resolution of the serous detachment.”

Another situation involved a patient in the ER with anterior uveitis and an apparent normal USG. After remission, when mapping the retina, the doctor noticed a peripheral blackened lesion. “Using the Eyer, I was able to document it. We redid the USG thinking it was a melanoma. And it was indeed a melanoma at the level of the ciliary body,” she says.

In children, the ophthalmologist recalls the care of two patients with slight vitreous hemorrhage: “After improving the transparency of the media, it was possible to record the presence of a slight vascular malformation at the level of the optic nerve,” she recalls.

Among the most commonly diagnosed diseases in babies are ROP, congenital infections, optic nerve hypoplasia and retinal and optic nerve colobomas. “I also use the Eyer a lot to quantify the size of the optic nerve and the excavation. This helps with the differential diagnosis of suspicious glaucomas, particularly in short-sighted children,” she concludes.

Below are some images taken by the ophthalmologist with the Eyer:

Img Imagem De Fundo De Olho Feita Com Eyer De Paciente Com Deslocamento De Retina

Patient with retinal displacement.

Img Imagem De Fundo De Olho Feita Com Eyer De Paciente Com Microembilizacoes Na Coroide Devido A Covid

Patient with microembolization  in the choroid due to covid.

Img Imagem De Fundo De Olho Feita Com Eyer De Paciente Com Oclusao Arterial

Patient with arterial occlusion.

The Eyer

The Eyer is a portable fundus camera that works in conjunction with a smartphone and performs high-quality retinal examinations in a few minutes without the need for pupil dilation.

The technology supports the diagnosis of more than 50 diseases, including glaucoma, cataracts, diabetic retinopathy, AMD, ROP, retinoblastoma, hypertensive retinopathy and ocular toxoplasmosis. Currently, more than 10 million tests have been carried out in Brazil, the United States, Chile, Colombia and Japan.

It was recently approved in the United Arab Emirates and is in the regulatory process of being marketed in Mexico, Egypt and Saudi Arabia.

Portability, connectivity and integration with intelligent functions such as EyerMaps, together with the technology’s affordability, contribute to increasing access to retinal examinations.

Study on Diabetic Retinopathy Screening Efficiency with Eyer Presented at ARVO

Study on Diabetic Retinopathy Screening Efficiency with Eyer Presented at ARVO

By 2030, over half a billion people are expected to be diagnosed with diabetes. Currently, Brazil ranks as the sixth country worldwide with the highest population of diabetics.

One of the most common complications of the disease is diabetic retinopathy, which is also one of the leading causes of preventable blindness in adults.

Currently, there is no national diabetic retinopathy screening strategy by the Unified Health System (SUS). Thus, social initiatives for diagnosing the disease in communities with inadequate healthcare infrastructure are crucial.

For instance, we have the “Mutirão do Diabetes” in Itabuna, Bahia, and “Iluminar” in the countryside of Sergipe, supported by the NGO Retina Global. This American institution focuses on developing sustainable solutions for managing retinal diseases in underserved areas around the world.

The countryside of Sergipe has high rates of illiteracy and lacks specialized retinal care outside the capital, Aracaju. To illustrate, the average number of annual laser treatments performed between 2017 and 2022 is merely 126 for a state population of 2.3 million.

From September 2021 to March 2022, “Iluminar” used the portable retinal camera, Eyer for diabetic retinopathy screening in Itabi, Graccho Cardoso, Canindé de São Francisco, and Poço Redondo.

tendências em tecnologia na saúde

The device is connected to a smartphone and performs retinal exams within minutes, producing high-quality images, and uploads the images to the EyerCloud online platform, facilitating remote assessments.

The results of the pilot project were presented at ARVO 2023, one of the most renowned international ophthalmology conferences held in the United States in April.

The Study

One of the leaders of the “Iluminar” project, ophthalmologist Fernando Malerbi, explains that the aim of the retrospective observational clinical study was to evaluate the grading capacity of retina images obtained using a low-cost, non-mydriatic portable retinal camera — in this case, the Eyer — along with the use of artificial intelligence and telemedicine for diabetic retinopathy screening.

In total, 968 individuals with diabetes were evaluated:

  • 65.9% were female;
  • Average age of 60.3 ± 14.2 years;
  • Duration of diabetes: 8.0 ± 7.2 years;
  • 64.2% had systemic hypertension;
  • 17.7% were using insulin; 
  • 28.5% had previously undergone fundus exams;
  • 20.6% were illiterate; 
  • 50.6% had only completed primary education; 
  • 3.4% had health insurance.

A trained technician captured images without pupil dilation and then assessed image quality. Diabetic retinopathy requiring referral, defined as severe non-proliferative or proliferative retinopathy or the presence of diabetic maculopathy, was automatically detected by an embedded artificial intelligence system (EyerMaps). The AI was provided for clinical validation.

In a matter of seconds, EyerMaps indicated the possibility of retinopathy with a high sensitivity rate. Subsequently, all exams were evaluated by ophthalmologists.

Patients with inadequate images underwent pupil dilation and then a new assessment. Those with non-gradable images even after mydriasis, along with cases of referable diabetic retinopathy, were referred for ophthalmological evaluation.

Corneal opacities that hindered retinopathy classification were the exclusion criteria. The primary outcome measure was image gradability.

The Results

Grading was possible for 858 individuals (88.6%), with 85 of these (9.9%) showing referable diabetic retinopathy. Non-grading was associated with older age and longer diabetes duration.

Among patients with gradable images, 81% did not require pupil dilation. The need for mydriasis was associated with older age, longer diabetes duration, higher hypertension rates, and more severe retinopathy.

The strategy of utilizing a low-cost portable camera with embedded AI system and mydriasis when necessary achieved suitable images in 90% of cases within a resource-limited real-world environment. Malerbi emphasizes, “Avoiding unnecessary pupil dilation contributes to higher adherence to diabetic retinopathy screening programs.”

Enhanced Portability Facilitated Screening

This novel screening was conducted in primary care clinics located near patients’ homes to encourage participation.

Malerbi highlights that the portability of Eyer was a facilitator, along with connectivity. “We had remote experts evaluating images, sometimes in real time,” he explains. All of the exams taken were uploaded to EyerCloud.

Lastly, Malerbi emphasizes the availability of EyerMaps for use in social initiatives. “Partner ophthalmologists were instantly notified whenever EyerMaps identified a high likelihood of retinopathy. Thus, we could prioritize patients for confirmatory exams and, if necessary, treatment,” he shares.

The AI accurately detects any suspicions of retinal abnormalities. Within seconds of capturing the fundus image, if an abnormality is detected, the system generates a new image with an attention map (heatmap) highlighting potential retinal anomalies.

Synchronized with EyerCloud, it categorizes images and exams captured based on the likelihood of abnormalities using color markers:

  • Green: Image or exam with low likelihood of an abnormality (up to 30%);
  • Yellow: Image or exam with moderate likelihood of an abnormality (31 to 70%);
  • Red: Image or exam with high likelihood of an abnormality (71 to 100%).

All patients diagnosed with diabetic retinopathy were referred for free laser treatment.

How Eyer Can Be Used in Neurology

How Eyer Can Be Used in Neurology

As the popular saying goes, the eyes are said to be the windows to the soul. When we apply this to the realm of healthcare, we might adapt it to say, “the eyes are the windows to the body.” This is because various diseases that affect our body manifest in the eyes.

Ophthalmologic exams can identify signs of abnormalities within our body, aiding in patient diagnosis. For instance, retinography and fundoscopy can detect infectious, chronic, vascular, hematologic, rheumatic, neurological disorders in addition to eye-related conditions.

In neurology,  headaches, cerebral aneurysms, multiple sclerosis, and intracranial hypertension — the latter of which can be related to brain tumors can all impact the structure of the orbit and eyeball. 

Since last year, neurologist Marcos Christiano Lange has been using Eyer, the portable retinal camera, to map a patient’s retina from the initial consultation. The device uses a built-in smartphone to conduct high-quality retinal exams within minutes, without the need for pupil dilation.

“Eyer is a significant help in screening. Besides being more convenient, when the attention map indicates potential abnormalities outside my field, I advise the patient to consult their ophthalmologist or refer the exam to a partnering ophthalmologist,” he explains.

Img Marcos Lange Blog
Neurologist Marcos Christiano Lange

This was how one of Lange’s patients was diagnosed with Age-Related Macular Degeneration (AMD). “She reported worsening vision, attributing it to possible cataracts. Upon examination, I observed protein accumulation in the macula and referred her to an ophthalmologist, who diagnosed AMD and initiated treatment. If I had performed a traditional eye fundus examination as a neurologist, focusing solely on the optic nerve, I wouldn’t have detected these findings,” he recalls.

Heatmap

Recently, Phelcom introduced a new feature: EyerMaps, an innovative Artificial Intelligence (AI) system that accurately detects any suspected retinal abnormalities.

Within seconds of capturing a photo of the eye’s fundus, if a suspicion of an abnormality is detected, the AI generates a new image with an attention map (heatmap) highlighting potential retinal abnormalities.

Synchronized with EyerCloud, Phelcom’s cloud-based system for patient data and exam management, the tool visually categorizes images and exams based on the probability of alteration, using color markers in the images and exams:

  • Green: Image or exam with low probability of abnormality (up to 30%);
  • Yellow: Image or exam with moderate probability of abnormality (31 to 70%);
  • Red: Image or exam with high probability of abnormality (71 to 100%).

The AI aids in diagnosing over 50 diseases, including diabetic retinopathy, hypertensive retinopathy, papilledema, and headaches. “I like to keep up with new technologies and am already familiar with Eyer. During a headache course I conducted, Phelcom provided the equipment for us to perform fundus assessments. After using it in practice, I decided to invest in acquiring the device,” he recalls.

EyerMaps

Since then, the neurologist has conducted over 400 exams with Eyer, all stored in EyerCloud for reports and tracking. “As soon as I capture the image, I upload it to the platform and open it on the computer to show the patient and explain the details in case of suspected pathology,” he says.

Eyer for Neurologists

For Lange, investing in a portable retinal camera like Eyer is important for neurologists to have an expanded view of the retina. “Even though retinal diseases aren’t our specialty, we can still assist the patient. And that’s priceless,” he emphasizes.

Another advantage is following up with patients who exhibit papilledema and degenerative diseases, such as diabetic retinopathy and hypertensive retinopathy.

Eyer

Eyer is a portable retinal camera that performs high-quality retinal exams in a few minutes, without the need for pupil dilation.

The technology is currently available in Brazil, the United States, Japan, Chile, Colombia, and will become available soon in other countries.

Portability, connectivity, and integration of intelligent functions like EyerMaps, along with the more accessible price, contribute to increased access to retinal exams.

About Phelcom

Phelcom Technologies is a Brazilian medtech company based in São Carlos, São Paulo. The company’s story begins in 2016, when three young researchers – a physicist, an electronic engineer, and a computer engineer (PHysics, ELectronics, COMputing) – created a portable retinal camera integrated with a smartphone.

The idea for the first prototype arose from co-founder Diego Lencione’s interest in visual health, as his brother had a condition that severely compromised his retina and vision since childhood.

In 2019, Phelcom launched its first product on the Brazilian market: the portable retinal camera, Eyer. More than 2 million people in Brazil and around the world have been examined by it so far.

In four years, the company has participated in over 100 social initiatives and was recently ranked among Brazil’s top 10 most innovative companies by Forbes Brazil.

New Feature: EyerMaps Detects possible retinal abnormalities in Real Time

New Feature: EyerMaps Detects possible retinal abnormalities in Real Time

Phelcom Technologies has just launched EyerMaps*, an innovative Artificial Intelligence (AI) system that runs embedded in the portable retinal camera, Eyer, and detects any suspicion of retinal abnormalities with high accuracy.

Within seconds of capturing the photo of the eye’s fundus, if an abnormality is detected, the AI generates a new image with an attention map (heatmap) highlighting potential retinal abnormalities. Synchronized with EyerCloud, Phelcom’s cloud-based system for patient data and exam management, the tool visually classifies captured images and exams based on the probability of abnormality, using colored markers on the images and exams:

  • Green: Image or exam with low probability of abnormality (up to 30%);
  • Yellow: Image or exam with moderate probability of abnormality (31 to 70%);
  • Red: Image or exam with high probability of abnormality (71 to 100%).
EyerMaps

Phelcom’s Co-Founder and CTO, Diego Lencione, explains how EyerMaps assists in ophthalmic clinical practice, “It’s important to emphasize that EyerMaps is not intended for diagnosing or referring patients. The system was developed to be a tool that aids the physician in the analysis and investigation of retinal changes, making ophthalmic care more agile and precise. Recognizing that we can all make mistakes, EyerMaps aims to be a tool that assists in detecting any retinal abnormality”. 

The AI can assist in detecting diseases such as glaucoma, Age-Related Macular Degeneration (AMD), diabetic retinopathy, hypertensive retinopathy, vascular tortuosity, occlusions, papilledema, retinitis pigmentosa, and nevi, among others.

“Minor changes can go unnoticed. And an assisting system like EyerMaps is precisely designed to assist the doctor in early diagnosis,” Lencione points out.

High Sensitivity and Specificity

EyerMaps

Lencione shares that EyerMaps is the result of five years of work by Phelcom in the field of artificial intelligence. “Since the foundation of Phelcom, we have maintained high investments in Research and Development. It’s in our DNA. Since 2018, we have been working on the development of EyerMaps, and I believe that one of the main merits of our team was to, after much effort, arrive at a highly accurate AI model that practically runs in real time on the Eyer, utilizing the high processing capacity of smartphones,” he explains.

The team tested the new feature in various social initiatives, such as the “Iluminar” project in the countryside of Sergipe and the Diabetes Mutirão in Itabuna (BA).

The results were analyzed and published in various articles, including the Journal of Diabetes Science and Technology. “In some studies focused on the detection of diabetic retinopathy, we have already achieved sensitivity and specificity with EyerMaps above 90%,” Lencione affirms.

EyerMaps

Phelcom’s Co-Founder and CTO emphasizes the importance of imaging and investigating the retina, not only for visual health but also for its power to reveal systemic, neurological, cardiac diseases, and more. “We created Eyer so that the retina can be more analyzed and studied by doctors, as we believe in the benefits this can bring to our society. When I see that nearly two million people have already been examined with Eyer, and some of them also with EyerMaps, I see that we are on the right path, fulfilling our mission as a company and as individuals by directly and indirectly helping to bring fundus exams to places and people that may not have been possible before.”

Phelcom  Eyer

The Phelcom Eyer is a portable retinal camera that attaches to a smartphone and performs high-quality retinal exams in minutes without the need for pupil dilation.

The technology supports the diagnosis of over 50 diseases, including glaucoma, cataracts, diabetic retinopathy, AMD, retinoblastoma, hypertensive retinopathy, and ocular toxoplasmosis. It is available in Brazil, the United States, Japan, Chile, Colombia, and will soon become available in other countries.

Portability, connectivity, and integration of intelligent functions like EyerMaps, along with a more accessible price, contribute to increased access to retinal exams.

EyerMaps

About Phelcom

Phelcom Technologies is a Brazilian medtech company headquartered in São Carlos, São Paulo. The company’s history began in 2016 when three young researchers – a physicist, an electronic engineer, and a computer engineer (PHysics, ELectronics, COMputing) – created a portable retinal camera integrated with a smartphone.

The idea for the first prototype arose from the interest of partner Diego Lencione in visual health, as his brother has a condition that severely compromised his retina and vision since childhood.

In 2019, Phelcom launched its first product in the Brazilian market: the portable retinal camera Eyer. More than 2 million people in Brazil and around the world have been examined using Eyer so far..

In four years, the company has participated in over 100 social initiatives and was recently listed among the top 10 most innovative companies in Brazil by Forbes.

*EyerMaps are designed for adult examination, do not substitute professional validation and can not be used alone for diagnostic purposes.

Phelcom’s Presence at Major International Trade Shows and Congresses

Phelcom’s Presence at Major International Trade Shows and Congresses

The company solidified its presence in the country by participating in significant events such as Vision Expo East, held from March 16 to 19 in New York, ARVO, from April 23 to 27 in New Orleans, and ASCRS, from May 5 to 8 in San Diego.

“These events bring forth many innovations, products, services, research, and advancements that not only keep us updated but also allow us to introduce Eyer to doctors, healthcare professionals, scientists, researchers, pharmaceutical companies, distributors, and potential partners in a relevant and swift manner,” emphasizes Phelcom’s International Manager, Mário Costa.

Phelcom showcased the portable retinal camera Eyer at the ARVO congress in 2023.

FDA Approves Eyer as 510(k)/FDA Cleared

Recently, the FDA (Food and Drug Administration) granted approval for Phelcom’s portable retinal camera, Eyer, as  510(k). Previously considered an exempt device, the technology was limited to patient photo documentation.

“Now, as we are FDA Cleared, Eyer can be used for diagnostic and telemedicine purposes. This new classification, the highest in our category, opens up more opportunities for our American clients to use our equipment both inside and outside the office,” Costa highlights.

Phelcom (20) (3) Menor

Upcoming International Events

Phelcom will take part in several international trade shows and congresses in the second half of the year. Check out the schedule:

AACO ANNUAL CONFERENCE 2023
August 18-20, Texas (US)
https://www.aacoeyes.org/2023-annual-conference-austin-tx

VISION EXPO WEST 2023
September 27-30, Las Vegas (US)
https://west.visionexpo.com/

ACADEMY 2023
October 11-14, New Orleans (US)
https://aaopt.org/meetings/annual-meeting/

AAO 2023
November 3-6, San Francisco (US)
https://www.aao.org/annual-meeting

Phelcom at the ASCRS congress in 2023.

Phelcom Eyer

Phelcom Eyer is a portable retinal camera that attaches to a smartphone and conducts high-quality retinal exams within minutes without the need for pupil dilation.

This technology aids in diagnosing over 50 diseases, including glaucoma, cataracts, diabetic retinopathy, AMD, retinoblastoma, hypertensive retinopathy, and ocular toxoplasmosis. It is available in Brazil, the United States, Japan, Chile, Colombia, and will soon become available in other countries.

Portability, connectivity, and integration with intelligent functions like EyerMaps, combined with the technology’s accessible price point, contribute to increased access to retinal exams.

About Phelcom

Phelcom Technologies is a Brazilian medtech company headquartered in São Carlos, São Paulo. The company’s story began in 2016 when three young researchers – a physicist, an electronic engineer, and a computer engineer (PHysics, ELectronics, COMputing) – created a portable retinal camera integrated with a smartphone.

The idea for the first prototype arose from the interest of partner Diego Lencione in visual health, driven by his brother’s condition, which severely affected his retina and vision since childhood.

In 2019, Phelcom introduced its first product to the Brazilian market: the portable retinal camera Eyer. More than 2 million people in Brazil and around the world have been examined using Eyer so far.

In four years, the company has participated in more than 100 social initiatives and was recently named among the 10 most innovative companies in Brazil by Forbes.

Eyer is approved in the United Arab Emirates

Eyer is approved in the United Arab Emirates

Recently, Phelcom visited the MENA region to train Allm MEA on using and presenting the Eyer retinal camera. This non-mydriatic device attaches to a smartphone and performs high-quality retinal examinations in just a few minutes.

The training took place at the Allm MEA office in Dubai, United Arab Emirates. “We conducted onboarding with our distributors, who are already highly qualified to demonstrate the advantages of Eyer to customers in the region,” emphasizes Phelcom’s International Business Manager, Mário Costa.

In addition, the Phelcom team visited significant hospitals in the United Arab Emirates, such as the Al Maerid Health Center MOH in Ras Al Khaimah and the Al Qassimi Hospital in Sharjah. At the latter, Eyer was introduced to the entire ophthalmology team.

Phelcom nos Emirados Árabes

Phelcom provided training on the use and commercial presentation of the portable retinal camera, Eyer, to their local partner and distributor, Allm MEA.

Pilot Project in Egypt

Phelcom has also conducted training on the use of Eyer at Ain Shams University Virtual Hospital (AVH) in Cairo, Egypt. “We are participating in a pilot project focused on teleophthalmology at AVH, which is responsible for one of the largest telemedicine programs in the country,” Costa explains.

The hospital develops technology-enabled healthcare systems in Egypt, the Middle East, and Africa. The project involves international collaborators and beneficiaries specializing in telemedicine, e-health research, artificial intelligence, virtual reality, and innovative healthcare models.

Phelcom no Emirados Árabes

Phelcom’s team during training on the use of Eyer at Ain Shams University Virtual Hospital.

Eyer is currently present in 6 countries.

Eyer was approved in the United Arab Emirates in the second quarter of this year. As a result, Phelcom now operates in six countries: Brazil, the United States, Japan, Chile, Colombia, and the United Arab Emirates.

Furthermore, the company is in the regulatory process for marketing Eyer in other locations such as Mexico, Egypt, and Saudi Arabia.

For Phelcom CEO, José Augusto Stuchi, being a Brazilian company operating in important global markets is a source of pride and great responsibility. “Internationalization undoubtedly expands our potential reach. However, it also increases our commitment to providing excellent quality products that truly benefit professionals,” he affirms.

Eyer

Phelcom (20) (3)

 Retina examination conducted with Eyer.

Eyer is a portable retinal camera that attaches to a smartphone and performs high-quality retinal examinations in minutes, without the need for pupil dilation.

The technology aids in the diagnosis of over 50 diseases, including glaucoma, cataracts, diabetic retinopathy, AMD, retinoblastoma, hypertensive retinopathy, and ocular toxoplasmosis. To date, more than 10 million examinations have been conducted in Brazil, the United States, Chile, and Colombia.

The portability and affordable price of the technology democratizes access to retinal examinations, costing approximately ten times less than a conventional tabletop retinal camera that still requires integration with a computer.

About Phelcom

Phelcom Technologies is a Brazilian medtech company based in São Carlos, São Paulo. The company’s story began in 2016 when three young researchers – a physicist, an electronic engineer, and a computer engineer (PHysics, ELectronics, COMputing) – created a portable retinal camera integrated with a smartphone.

The idea for the first prototype emerged from the interest of co-founder Diego Lencione in visual health, as his brother has a condition that severely affects the retina and vision that he’s had since childhood.

In 2019, Phelcom launched its first product, the portable retinal camera Eyer, to the Brazilian market. Today, the technology has reached over two million people throughout Brazil and other countries it is present in..

In four years, the company has participated in over 100 social initiatives and was recently named one of the top 10 most innovative companies in Brazil by Forbes.

Icon Button Request A QuoteRequest a Quote

Fechar

Ico Back

Later

Request a quote

Fill out the form below and we will contact you shortly.

    Ico Form Success

    Request a Quote

    Our team will contact you shortly.

    Close

    …complete suas informações

      By clicking the Complete button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
      Ico Back

      Depois

      Ico Form Success

      Obrigado por completar suas informações

      FECHAR

      Ico Back

      Depois

      Solicite e comece SEU TEST DRIVE

      Por favor, preencha o formulário abaixo que entraremos em contato.

        x

        Solicitar Orçamento

        Ao clicar em Solicitar, concordo com a Política de Privacidade e os Termos de Uso, permito que a Phelcom me contate e reconheço que o Eyer é um dispositivo médico (Anvisa classe II) exigindo a supervisão de um profissional com CRM para uso e interpretação das imagens.
        Ico Form Success

        Obrigado!

        Nosso time comercial logo entrará em contato para finalizar o processo.

        FECHAR

        Ico Back

        Later

        Request more information

        Please fill out the form below and we will contact you.

          x

          Request EyerMaps

          By clicking the Request button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
          Ico Form Success

          Thank you!

          Our commercial team will contact you shortly to finalize the process.Our commercial team will contact you shortly to finalize the process.
          CLOSE